文献速递糖尿病

空腹血糖变异预测ACCORD与VADT试验中的微血管风险

Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究基于ACCORD和VADT两项试验的事后分析,评估2型糖尿病患者空腹血糖变异与微血管并发症的关系。

要点

  • 空腹血糖变异系数和平均真实变异度可独立预测微血管并发症。
  • 该关联独立于平均血糖控制水平(如HbA1c累积平均值)。
  • 血糖控制不严格者中空腹血糖变异的危害可能更明显。

核心结论

  • 空腹血糖变异是2型糖尿病微血管并发症发生发展的独立且易获取的标志物。

研究设计与样本

  • VADT试验中1791人每3个月测量空腹血糖,最长87个月。
  • 采用Cox比例风险模型将变异指标作为时间依赖协变量分析。
  • 对两项试验进行Meta分析以评估风险及治疗臂间的异质性效应。

主要发现

  • ACCORD和VADT中空腹血糖的变异系数和平均真实变异度均与未来微血管结局相关。
  • 调整包括HbA1c累积平均值在内的其他风险因素后关联仍显著。
  • Meta分析确认上述发现,并提示血糖控制不严格者空腹血糖变异可能更有害。

临床怎么用

  • 在2型糖尿病管理中,除平均血糖外应关注空腹血糖变异系数和平均真实变异度。
  • 空腹血糖变异可作为微血管并发症风险的简易预警指标。

局限性

  • 本研究为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The association of glycemic variability with microvascular disease complications in type 2 diabetes (T2D) has been under-studied and remains unclear. We investigated this relationship using both Action to Control Cardiovascular Risk in Diabetes (ACCORD) and the Veteran Affairs Diabetes Trial (VADT). METHODS: In ACCORD, fasting plasma glucose (FPG) was measured 1 to 3 times/year for up to 84 months in 10 251 individuals. In the VADT, FPG was measured every 3 months for up to 87 months in 1791 individuals. Variability measures included coefficient of variation (CV) and average real variability (ARV) for fasting glucose. The primary composite outcome was time to either severe nephropathy or retinopathy event and secondary outcomes included each outcome individually. To assess the association, we considered variability measures as time-dependent covariates in Cox proportional hazard models. We conducted a meta-analysis across the 2 trials to estimate the risk of fasting glucose variability as well as to assess the heterogenous effects of FPG variability across treatment arms. RESULTS: In both ACCORD and the VADT, the CV and ARV of FPG were associated with development of future microvascular outcomes even after adjusting for other risk factors, including measures of average glycemic control (ie, cumulative average of HbA1c). Meta-analyses of these 2 trials confirmed these findings and indicated FPG variation may be more harmful in those with less intensive glucose control. CONCLUSIONS: This post hoc analysis indicates that variability of FPG plays a role in, and/or is an independent and readily available marker of, development of microvascular complications in T2D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zhou JJ, Koska J, Bahn G, et al. Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT. J Clin Endocrinol Metab. 2021. PMID: 33367811. doi:10.1210/clinem/dgaa941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。